GH Research (GHRS) Operating Expenses (2020 - 2026)
GH Research (GHRS) posted quarterly Operating Expenses of -$71.5 million for Q4 2025, down 7.37% year-over-year from -$77.2 million in Q4 2024, and down 1664.26% quarter-over-quarter from $4.6 million in Q3 2025.
Analysis
GH Research (GHRS) Operating Expenses (2020 - 2026) Analysis & Trends
GH Research's Operating Expenses history runs 6 years deep, the most recent figure standing at -$71.5 million for Q4 2025.
- In Q4 2025, Operating Expenses fell 7.37% year-over-year to -$71.5 million; the TTM figure through Dec 2025 stood at -$60.7 million (down 20.68% YoY), while the FY2025 annual figure was $60.7 million, up 20.68% from the prior year.
- Operating Expenses for Q4 2025 stood at -$71.5 million, down from $4.6 million in the prior quarter.
- The five-year high for Operating Expenses was $28.1 million in Q4 2023, with the low at -$71.5 million in Q4 2025.
- The 5-year median for Operating Expenses is $3.7 million (2024), against an average of -$1.7 million.
- Peak annual rise in Operating Expenses reached 4058.55% in 2021, while the deepest fall reached 7676.67% in 2021.
- GH Research's Operating Expenses stood at $23.6 million in 2021, then increased by 5.13% to $24.8 million in 2022, then climbed by 13.54% to $28.1 million in 2023, then sank by 336.5% to -$66.6 million in 2024, then dropped by 7.37% to -$71.5 million in 2025.
- Business Quant data shows GHRS's Operating Expenses at -$71.5 million in Q4 2025, $4.6 million in Q3 2025, and $3.2 million in Q2 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Opex (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.31 Bn | 131.46 Bn | 2.84 Bn | 2.09 Bn |
| 2 | Regeneron Pharmaceuticals | 85.65 Bn | 77.66 Bn | 3.93 Bn | 3.00 Bn |
| 3 | Argenx Se | 63.46 Bn | 58.27 Bn | 1.37 Bn | -1.05 Bn |
| 4 | Moderna | 57.94 Bn | 52.80 Bn | 52.00 Mn | 960.00 Mn |
| 5 | Revolution Medicines | 44.05 Bn | 44.05 Bn | - | 505.13 Mn |
| 6 | BeOne Medicines | 39.96 Bn | 34.86 Bn | 1.53 Bn | 1.21 Bn |
| 7 | Alnylam Pharmaceuticals | 35.16 Bn | 31.85 Bn | 992.69 Mn | 1.06 Bn |
| 8 | Royalty Pharma | 28.44 Bn | 27.60 Bn | - | 541.02 Mn |
| 9 | Insmed | 27.32 Bn | 26.16 Bn | 358.27 Mn | 427.03 Mn |
| 10 | GH Research | 1.71 Bn | 1.34 Bn | - | 5.34 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 5.34 Mn |
| Mar 31, 2026 | 6.01 Mn |
| Dec 31, 2025 | -71.47 Mn |
| Sep 30, 2025 | 4.57 Mn |
| Jun 30, 2025 | 3.21 Mn |
| Mar 31, 2025 | 2.97 Mn |
| Dec 31, 2024 | -66.56 Mn |
| Sep 30, 2024 | 4.17 Mn |
| Jun 30, 2024 | 6.29 Mn |
| Mar 31, 2024 | 5.79 Mn |
| Dec 31, 2023 | 5.34 Mn |
| Sep 30, 2023 | 4.46 Mn |
| Jun 30, 2023 | 4.43 Mn |
| Mar 31, 2023 | 4.19 Mn |
| Dec 31, 2022 | 24.79 Mn |
| Sep 30, 2022 | 2.61 Mn |
| Jun 30, 2022 | 1.73 Mn |
| Mar 31, 2022 | -8.01 Mn |
| Dec 31, 2021 | 10.49 Mn |
| Sep 30, 2021 | -4.67 Mn |